
In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.

In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.

In part 1 of this video interview, Vincent Keunen, founder & CEO of Andaman7 discusses how service providers and sponsors can make the lives of patients contributing to research easier.

In the fifth and final part of this video interview, Rama Kondru, PhD, CEO of Veridix AI looks forward to what the LLM landscape in clinical trials could look like in five years.

In part 4 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses best practices for choosing the right artificial intelligence solutions.

In part 3 of this video interview, Rama Kondru, PhD, CEO of Veridix AI touches on how large language models can leverage unstructured data.

In part 2 of this video interview, Rama Kondru, PhD, CEO of Veridix AI highlights areas that large language models can be used in clinical trials including patient recruitment and retention.

In part 1 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses challenges with adoption and the potential uses of large language models in clinical trials.

In the fifth and final part of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA touches on how the organization continues to break down silos in clinical research and provide a medium for collaboration.

In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the clinical research industry.

In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.

Carie Pierce, SVP, global head of growth & business development, DIA touches on the various themes of the sessions which were held at the 2024 Global Annual Meeting including regulatory, technology, and harmonization.

Pierce shares her greatest takeaways from this year's meeting in San Diego, CA.

Del Smith, PhD, co-founder & CEO of Acclinate highlights challenges sponsors may face in light of FDA releasing its Diversity Action Plan guidance.

Smith shares his initial thoughts on the guidance and what its impact will be on the industry moving forward.

In the fourth and final part of this video interview, Kristy Birchard, product owner, patient engagement, YPrime discusses the importance of designing products based on the experience of patients.

In part 3 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime touches on the importance of utilizing patient-reported outcomes.

In part 2 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime discusses the work she is currently doing within patient centricity and how to effectively reach patient communities.

In part 1 of this video interview, Kristy Birchard, product owner, patient engagement, YPrime highlights the importance of patient centricity in trial design.

Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit highlight the potential impact FDA's Diversity Action Plan guidance will have on industry.

Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit share their initial thoughts on the announcement of FDA's Diversity Action Plan guidance.

In the fifth and final part of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions looks to the future and touches on what the use of AI in clinical trials could like in five years.

In part 4 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions discusses what industry stakeholders should be keeping top of mind when integrating AI into their workflows.

In part 3 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions touches on some of the greatest benefits she has seen with the integration of artificial intelligence into data management.

In part 2 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions highlights how artificial intelligence can help industry keep pace with the increasing complexity of data.

In part 1 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions discusses the current landscape of data collection in clinical trials and the growing complexity of protocols.

In an interview with ACT editor Andy Studna at DIA 2024, Beakes-Read, head, global regulatory policy and intelligence, Johnson & Johnson Innovative Medicine highlights the integration of technological advancements into drug development and benefits patients are seeing from FDA's Accelerated Approval Program.

In an interview with ACT editor Andy Studna at DIA 2024, Cuff Shimooka, chief operating officer of TransCelerate Biopharma touches on how collaboration will be key to innovation in clinical research moving forward.

In an interview with ACT editor Andy Studna at DIA 2024, DiCicco, vice president, portfolio management, TransCelerate Biopharma highlights the use of artificial intelligence in clinical research from the perspectives of different stakeholders.